Weekly Endocrinology Research Analysis
This week’s endocrinology literature highlights three high-impact directions: genotype-specific metabolic effects of widely used agents (melatonin impairing β-cell function in MTNR1B risk carriers), advance of oral small-molecule GLP‑1 receptor agonists achieving clinically meaningful weight loss (HRS‑7535), and mechanistic stratification of GLP‑1 action by metabolic state (brain vs islet). Together these findings push precision prescribing, broaden therapeutic delivery options beyond injectable
Summary
This week’s endocrinology literature highlights three high-impact directions: genotype-specific metabolic effects of widely used agents (melatonin impairing β-cell function in MTNR1B risk carriers), advance of oral small-molecule GLP‑1 receptor agonists achieving clinically meaningful weight loss (HRS‑7535), and mechanistic stratification of GLP‑1 action by metabolic state (brain vs islet). Together these findings push precision prescribing, broaden therapeutic delivery options beyond injectables, and reinforce metabolic-state informed patient selection for incretin therapies.
Selected Articles
1. Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant.
Randomized, double‑blind, placebo‑controlled crossover trial in 21 healthy adults showed that a single 5 mg melatonin dose acutely worsened glucose tolerance and suppressed first‑phase β‑cell responsivity by ~40% in MTNR1B G‑allele carriers but not in noncarriers; melatonin also altered insulin feedback and prevented insulin‑induced hypoglycaemia in carriers, delineating genotype‑specific metabolic harm.
Impact: Provides high‑quality, mechanistic, genotype‑stratified RCT evidence that a commonly used supplement (melatonin) can acutely impair β‑cell function in genetic risk carriers, directly informing personalized counseling and risk mitigation.
Clinical Implications: Consider counseling patients—especially those with prediabetes or family risk—about melatonin use; where available, MTNR1B genotype could inform sleep‑aid recommendations and timing/dose strategies pending larger chronic studies.
Key Findings
- Melatonin worsened glucose tolerance in MTNR1B G‑allele carriers but not in noncarriers.
- First‑phase β‑cell responsivity to glucose was suppressed by ~40% in carriers under melatonin.
- Melatonin slowed insulin‑induced decline in second‑phase insulin secretion and prevented insulin‑induced hypoglycaemia in carriers.
2. HRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.
Multicenter randomized double‑blind phase 2 trial (n=235) showed once‑daily oral HRS‑7535 produced dose‑dependent weight loss at 26 weeks (up to −9.36% at 180 mg; placebo‑adjusted up to −6.87% for highest dose) with mostly mild‑to‑moderate GI adverse events, supporting the feasibility of an oral GLP‑1 therapeutic class.
Impact: First randomized phase 2 evidence that an oral small‑molecule GLP‑1RA can achieve clinically meaningful weight loss, potentially expanding access and adherence beyond injectable incretins and reshaping therapeutic delivery paradigms in obesity care.
Clinical Implications: If replicated in larger, longer trials with diverse populations and active comparators, oral GLP‑1RAs could become an alternative to injectables for obesity management, improving patient choice and potentially adherence.
Key Findings
- Dose-dependent weight loss at 26 weeks: LS mean changes −2.99% (30 mg), −7.09% (60 mg), −6.17% (120 mg), −9.36% (180 mg) vs −2.50% placebo.
- Placebo-adjusted differences reached statistical significance for 60 mg and above (largest placebo-adjusted −6.87%).
- Gastrointestinal adverse events were the most common, mainly mild‑to‑moderate and occurring more during dose escalation.
3. Metabolic state determines the brain and direct islet effects of liraglutide on enhanced insulin secretion.
Translational mechanistic study using human donor islets across metabolic states found liraglutide enhances glucose‑stimulated insulin secretion in islets from glucose‑intolerant donors but not in normoglycaemic donors; GLP‑1R expression declined with rising HbA1c, and complementary mechanisms (tanycyte‑mediated brain actions in health vs direct islet effects in glucose intolerance) were delineated—supporting metabolic‑state guided patient stratification for GLP‑1RA therapy.
Impact: Provides mechanistic human‑tissue evidence that the predominant site and efficacy of GLP‑1RA action depend on metabolic state, informing precision pharmacology and potential biomarker‑guided therapy selection.
Clinical Implications: Supports stratifying patients by metabolic phenotype when predicting GLP‑1RA response: those with glucose intolerance may get greater islet secretory benefit, while early/healthy states may derive brain‑mediated effects—motivating biomarker development for clinical decision‑making.
Key Findings
- Liraglutide enhanced glucose‑stimulated insulin secretion in islets from glucose‑intolerant donors (n=7) but not in normoglycaemic donors (n=7).
- GLP‑1R mRNA levels in T2D donor islets declined with increasing HbA1c, indicating receptor‑level changes with metabolic deterioration.
- Mechanistic framework: tanycyte‑mediated central actions predominate in healthy states; direct islet effects emerge during glucose intolerance; insulin‑independent pathways contribute across states.